Highest-materiality recent filing
MiniMed Q4 net sales $837M (+16% as reported); FY27 organic growth guidance ~10%
Q4 net sales $837M (+15.6% as reported, +8.7% organic); International $599M (+22.4% as reported, +12.2% organic).
MiniMed Flex insulin pump receives FDA clearance months early; $157M charge expected in Q4 FY2026
FDA cleared MiniMed Flex insulin pump several months earlier than expected, enabling earlier commercialization.
MiniMed Group completes IPO, raises ~$560M; Medtronic retains 90% ownership
IPO of 28M shares at $20/share; net proceeds ~$560M; $309M retained for corporate purposes, excess repays Medtronic intercompany debt.
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall’s departure.
On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) and member of the Board’s Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026.
Max materiality 1.00 · Median 0.55 · Most common event leadership